Core Viewpoint - Akebia Therapeutics, Inc. is a biopharmaceutical company focused on therapies for kidney disease, facing competition in the industry [1] Financial Performance - Akebia is set to release its quarterly earnings on November 10, 2025, with Wall Street estimating earnings per share at -$0.02 and projected revenue of approximately $58.2 million [2] - The company has a negative price-to-earnings (P/E) ratio of -14.47, while the price-to-sales ratio is about 2.62, indicating investors are paying $2.62 for every dollar of sales [3] - The enterprise value to sales ratio is approximately 2.20, reflecting the company's valuation relative to its revenue [3] Cash Flow and Financial Ratios - The enterprise value to operating cash flow ratio is significantly negative at around -186.85, indicating challenges in generating cash flow from operations [4] - The earnings yield is negative at approximately -6.91%, further highlighting financial difficulties for Akebia [4] - The debt-to-equity ratio stands at 1.83, suggesting a relatively high level of debt compared to equity, while the current ratio is approximately 1.98, indicating a reasonable level of short-term financial health [5]